Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway
Koji Ando(Boston University), Ajit Bharti(Boston University), J. Keith Joung(Massachusetts General Hospital), Ankur K. Shah(Boston University), Yiheng Hu(Chinese Academy of Sciences), Jeffrey D. Parvin(The Ohio State University), Julian Taylor‐Parker(Boston University), Vibhu Sachdev(Boston University), Lucia E. Rameh(University of South Alabama), Benjamin P. Kleinstiver(Harvard University), Moira M. Welch(Massachusetts General Hospital), Forest M. White(Center for Cancer Research), Al Ozonoff(Boston Children's Hospital), Ravi Salgia(City Of Hope National Medical Center)
Cited by 27
Related Papers
High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells
|Nature Biotechnology|2013|3.3k
CRISPR-Cas systems for editing, regulating and targeting genomes
|Nature Biotechnology|2014|3.2k
Efficient genome editing in zebrafish using a CRISPR-Cas system
|Nature Biotechnology|2013|3k
High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effects
|Nature|2016|2.7k
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
|Nature Biotechnology|2014|2.3k